XBiotech Inc. — Q1 2018 Form 10-Q Summary
Business context and period: XBiotech is a pre-commercial biopharmaceutical company developing naturally occurring “True Human” monoclonal antibodies. This unaudited report covers the three months ended March 31, 2018, compared with Q1 2017; balance-sheet amounts are compared with December 31, 2017. The company reported 40 employees and no product revenue.
Key financial results
| Metric | Q1 2018 | Q1 2017 / prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.0 million | $8.2 million |
| General and administrative expense | $1.2 million | $2.1 million |
| Total operating expenses / operating loss | $4.2 million | $10.3 million |
| Net loss | $4.1 million | $10.6 million |
| Basic and diluted loss per share | $0.11 | $0.32 |
| Operating cash used | $3.5 million | $11.9 million |
| Cash and cash equivalents, March 31, 2018 | $28.4 million | $31.8 million at Dec. 31, 2017 |
| Total assets / shareholders’ equity, March 31, 2018 | $58.9 million / $56.4 million | $63.0 million / $60.2 million at Dec. 31, 2017 |
| Total liabilities, March 31, 2018 | $2.5 million | $2.8 million at Dec. 31, 2017 |
There is no reported revenue or gross margin; conventional profitability margins are not meaningful for this pre-market company. No debt is reported on the balance sheet. Current assets were $29.7 million and current liabilities $2.4 million at quarter-end. The company’s accumulated deficit was $220.6 million.
Changes and management commentary
- Net loss narrowed by about 61% year over year, primarily because research and development costs declined 63%, reflecting completion or discontinuation of active Phase III colorectal cancer trials, reduced clinical-trial activity and manufacturing, and a smaller workforce. R&D headcount fell from 93 to 35; total headcount was 40 at quarter-end.
- General and administrative expense declined 44%, partly due to lower share-based compensation, professional fees, and administrative staffing.
- Management announced two open-label Phase II dose-escalation studies of subcutaneous MABp1 for moderate-to-severe atopic dermatitis and hidradenitis suppurativa. Planned treatment periods are four weeks and 12 weeks, respectively; results are intended to inform potential further randomized studies.
- Cash decreased by $3.4 million during the quarter. Financing provided $0.2 million from option exercises; the comparable 2017 quarter included $32.7 million of financing, primarily an equity offering.
- Management stated that March 31 cash was expected to fund operating and capital needs through 2019 and support certain clinical and preclinical milestones. This estimate depends on assumptions that may prove incorrect; the company expects substantial future losses and may need additional financing. It has never been profitable and says it will require significant revenue to achieve profitability.
Risks, contingencies, and other items
- A securities class action concerning statements about the European Phase III Xilonix colorectal cancer trial remained pending in Texas state court. The company considers the claims without merit and intends to defend itself; damages sought are unspecified.
- The company disclosed $433,000 of future minimum facility lease payments, all due within one year, and quarterly rent expense of $200,000.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. It reported no material changes to the risk factors in its 2017 Form 10-K.
- The company cited risks including clinical and regulatory uncertainty, commercialization and financing needs, competition, intellectual-property protection, and its ability to recruit and retain personnel. It reported no material market-risk exposure requiring hedging.
Most important facts for investors to verify
- Whether the announced MABp1 Phase II studies enroll and progress as planned, and whether their results support larger controlled trials.
- Whether the stated cash runway through 2019 remains credible as clinical spending changes; Q1 operating cash use was $3.5 million and cash was $28.4 million at quarter-end.
- How spending and development plans evolve after the Phase III colorectal cancer trials were completed or discontinued, and whether new programs increase cash burn.
- Developments and potential financial exposure in the pending securities litigation.
- The filing reports $28.4 million of cash on the balance sheet; management’s discussion separately refers to approximately $28.0 million. Verify the precise cash figure against the financial statements.